Al Lawati Hanan, Al Busaidi Sara, Al Rawahi Thuraiya, Al Lawati Abdullah, Kifah Ahmed, Das Srijit
Department of Pharmaceutics, Oman College of Health Sciences, Muscat, Oman.
Medical Department, Sultan Qaboos University, Muscat, Sultanate of Oman.
Curr Pharm Des. 2025;31(1):26-36. doi: 10.2174/0113816128310838240820065324.
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing bisphosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.
骨质疏松症是一个重大的全球健康问题。老年人骨质疏松症发病率的上升对治疗构成了挑战，也给国家带来了经济负担。骨质疏松症在女性中受到了更多关注，而在男性中应对这种疾病也变得刻不容缓。各种药物，如含氮双膦酸盐、核因子κB受体活化因子配体（RANKL）抑制剂、甲状旁腺激素和阿仑膦酸钠，已被用于有效治疗骨质疏松症。阿仑膦酸钠（阿仑膦酸）是一种含氮双膦酸盐，可抑制破骨细胞的骨吸收，于20世纪70年代合成。在本综述中，我们讨论了阿仑膦酸钠的药代动力学、作用机制、不良反应、禁忌证和毒性监测。该药物可有效用于治疗男性骨质疏松症，以增加骨矿物质密度并预防骨折。
